广发中证香港创新药ETF(QDII)(513120)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
1,222,933,646.16 |
-636,586,176.46 |
-444,025,219.09 |
-22,630,260.87 |
| 本期利润 |
4,665,937,493.62 |
-734,579,012.91 |
-1,715,632,048.61 |
-646,108,205.13 |
| 加权平均基金份额本期利润 |
0.39 |
-0.08 |
-0.20 |
-0.18 |
| 本期加权平均净值利润率(%) |
44.90 |
-12.45 |
-31.05 |
-21.60 |
| 本期基金份额净值增长率(%) |
57.12 |
-9.73 |
-25.34 |
-18.93 |
| 期末可供分配利润 |
43,665,221.78 |
-3,045,376,863.32 |
-3,353,424,887.03 |
-1,707,927,832.33 |
| 期末可供分配基金份额利润 |
0.00 |
-0.28 |
-0.40 |
-0.20 |
| 期末基金资产净值 |
13,424,134,958.37 |
7,875,258,558.68 |
4,955,210,534.97 |
6,780,707,589.67 |
| 期末基金份额净值 |
1.13 |
0.72 |
0.60 |
0.80 |
| 基金份额累计净值增长率(%) |
13.30 |
-27.89 |
-40.36 |
-20.12 |
微信公众号
证券之星APP
基本资料
